Comparable outcomes, different toxicities with anastrozole, tamoxifen in DCIS

Ivana Sestak puts the long-term results of the IBIS-II trial in the context of the NSABP B-35 study, both of which compared anastrozole with tamoxifen for breast cancer prevention in postmenopausal women with HR-positive ductal carcinoma in situ (3:39).